Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical pharmacology and therapy

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2013.174PMID 24013811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

  2015cited by this paper
• Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

  2014cited by this paper
• Filomicelles in nanomedicine - from flexible, fragmentable, and ligand-targetable drug carrier designs to combination therapy for brain tumors.

  2013cited by this paper
• First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

  2013cited by this paper
• Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel.

  2013cited by this paper
• Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine.

  2013cited by this paper
• CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

  2012cited by this paper
• Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

  2012cited by this paper
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

  2012cited by this paper
• Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

  2012cited by this paper
• Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

  2012cited by this paper
• Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

  2012cited by this paper
• Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum

  2012cited by this paper
• More effective nanomedicines through particle design.

  2011cited by this paper
• Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.

  2011cited by this paper
• Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

  2011cited by this paper
• Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

  2011cited by this paper
• Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.

  2011cited by this paper
• A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

  2011cited by this paper
• Paclitaxel poliglumex for ovarian cancer

  2011cited by this paper
• Overcoming in vivo barriers to targeted nanodelivery.

  2011cited by this paper
• A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

  2011cited by this paper
• Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo

  2011cited by this paper
• Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors

  2010cited by this paper
• Effect of surface properties on nanoparticle-cell interactions.

  2010cited by this paper
• Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.

  2010cited by this paper
• The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• A report from the Childhood Cancer Survivor Study (CCSS): cancer related posttraumatic stress symptoms, depression, anxiety, and chronic pain in adult childhood cancer survivors

  2009cited by this paper
• Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies

  2009cited by this paper
• A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

  2009cited by this paper
• A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin.

  2009cited by this paper
• Update on developmental therapeutics for acute lymphoblastic leukemia

  2009cited by this paper
• Particle size-dependent triggering of accelerated blood clearance phenomenon.

  2008cited by this paper
• Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

  2008cited by this paper
• Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.

  2008cited by this paper
• Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

  2008cited by this paper
• Nanoparticle-mediated cellular response is size-dependent.

  2008cited by this paper
• Nanoparticle therapeutics: an emerging treatment modality for cancer

  2008cited by this paper
• Targeted pharmaceutical nanocarriers for cancer therapy and imaging

  2007cited by this paper
• Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

  2007cited by this paper
• Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.

  2007cited by this paper
• Shape effects of filaments versus spherical particles in flow and drug delivery.

  2007cited by this paper
• Renal clearance of quantum dots

  2007cited by this paper
• Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

  2006cited by this paper
• Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.

  2006cited by this paper
• Adverse psychological effects of corticosteroids in children and adolescents

  2005cited by this paper
• Cell-specific targeting of nanoparticles by multivalent attachment of small molecules

  2005cited by this paper
• Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

  2005cited by this paper
• Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

  2004cited by this paper
• Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

  2004cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

  2004cited by this paper
• Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

  2004cited by this paper
• Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance

  2002cited by this paper
• p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

  2001cited by this paper
• Long-circulating and target-specific nanoparticles: theory to practice.

  2001cited by this paper
• On the importance and mechanisms of burst release in matrix-controlled drug delivery systems.

  2001cited by this paper
• Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge.

  2001cited by this paper
• HIGH-DOSE METHOTREXATE IN CHILDHOOD ALL

  2000cited by this paper
• Use of L-asparaginase in childhood ALL.

  1998cited by this paper
• Changing bone marrow micro‐environment during development of acute myeloid leukaemia in rats

  1998cited by this paper
• Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

  1997cited by this paper
• [From theory to practice].

  1997cited by this paper
• Infectious and immunosuppressive complications of purine analog therapy.

  1995cited by this paper
• Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations

  1994cited by this paper
• Cytarabine and neurologic toxicity.

  1991cited by this paper
• Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

  1991cited by this paper
• Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia

  1991cited by this paper
• Serum-induced leakage of liposome contents.

  1980cited by this paper
• Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

  1977cited by this paper
• Evidence That Drugs in Multiple Combinations Have Materially Advanced the Treatment of Human Malignancies

  1969cited by this paper
• Vincristine‐induced neuropathy

  1969cited by this paper
• The Principles of Chemotherapy

  1952cited by this paper
• CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATINIB _________________________________________________________

  year unknowncited by this paper

• Evaluation of the Proliferative Effects of Hexagonal Boron Nitride Nanoparticles on Leukemia Cells and Leukemia Stem Cells

  2024cites this paper
• Spleen-liver dual accumulation of ly6clowExo potentiates synergistic immune modulation for liver fibrosis therapy

  2024cites this paper
• Copper-Based Nanomaterials for Image-Guided Cancer Therapy

  2024cites this paper
• Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology

  2024cites this paper
• Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

  2023cites this paper
• Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

  2023cites this paper
• Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review

  2022cites this paper
• Two-dimensional (2D) hybrid nanomaterials for diagnosis and treatment of cancer

  2022cites this paper
• Nanoformulations-based advancement in the delivery of phytopharmaceuticals for skin cancer management

  2021cites this paper
• 6‐Shogaol induces apoptosis in acute lymphoblastic leukaemia cells by targeting p53 signalling pathway and generation of reactive oxygen species

  2021cites this paper
• Current Advances in Black Phosphorus‐Based Drug Delivery Systems for Cancer Therapy

  2021cites this paper
• Synthesis of pH-responsive triazine skeleton nano-polymer composite containing AIE group for drug delivery

  2021cites this paper
• Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma.

  2021cites this paper
• Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.

  2021cites this paper
• A new pH/NIR responsive theranostic agent for magnetic resonance imaging guided synergistic therapy

  2021cites this paper
• Polyphosphazene-Based Drug Self-Framed Delivery System as a Universal Intelligent Platform for Combination Therapy against Multidrug-Resistant Tumors.

  2020cites this paper
• Effects of Rehmannia glutinosa polysaccharides on the proliferation and apoptosis of K562 cells.

  2020cites this paper
• Hypoxia-Responsive Polymeric Micelles for Enhancing Cancer Treatment

  2020cites this paper
• Nanoparticles for topical drug delivery: Potential for skin cancer.

  2020cites this paper
• An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites

  2019cites this paper
• Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers.

  2019cites this paper
• Click Nucleic Acid Mediated Loading of Prodrug Activating Enzymes in PEG-PLGA Nanoparticles for Combination Chemotherapy.

  2019cites this paper
• Reduction and pH dual-sensitive nanovesicles co-delivering doxorubicin and gefitinib for effective tumor therapy

  2018cites this paper
• A DOX-loaded polymer micelle for effectively inhibiting cancer cells

  2018cites this paper
• FPOA induces the apoptosis of HepG2 cells.

  2018cites this paper
• Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy

  2018cites this paper
• Nanomedicines for Pediatric Cancers.

  2018cites this paper
• Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.

  2017cites this paper
• Examination of potential mechanisms linking AMPK to inhibition of IL-6 signalling

  2017cites this paper
• Nanomedicine approaches in acute lymphoblastic leukemia.

  2016cites this paper
• Erratum to: Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment

  2016cites this paper
• Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.

  2016cites this paper
• Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment

  2016cites this paper
• Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells.

  2016cites this paper
• "Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy.

  2016cites this paper
• Size Matters: Developing Design Rules to Engineer Nanoparticles for Solid Tumour Targeting

  2015cites this paper
• CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia.

  2015cites this paper
• Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity.

  2015cites this paper
• Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment

  2015cites this paper
• Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy

  2015cites this paper
• Bioengineering targeted nanodrugs for hematologic malignancies: An innovation in pediatric oncology

  2015cites this paper
• Nanomedicine to Mitigate Toxic Side-Effects of Chemotherapy in Children

  2014cites this paper
• Targeted Nanoparticles for Pediatric Leukemia Therapy

  2014cites this paper
• Chemotherapy in children

  2014cites this paper
• Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics

  2014cites this paper
• Targeted therapy with MXD3 siRNA, anti‐CD22 antibody and nanoparticles for precursor B‐cell acute lymphoblastic leukaemia

  2014cites this paper
• Bibliometric Analysis of Nanotechnology Applied in Colon Cancer Screening and Therapy from 2002 to 2011

  2014cites this paper
• therapeutic strategies. The exploration of innovative nanoplatforms that integrate diagnostics and therapeutics

  year unknowncites this paper